The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis

Authors

  • Ian Wright vesia [Alberta Bladder Centre]
  • Andrea Civitarese vesia [Alberta Bladder Centre]
  • Richard Baverstock vesia [Alberta Bladder Centre] University of Calgary

DOI:

https://doi.org/10.5489/cuaj.3678

Abstract

The use of intra-detrusor onabotulinumtoxinA (Botox®) in patients with myasthenia gravis has not been reported, and little evidence exists to substantiate a complete contraindication of Botox use in this population. Here, we present two cases of comorbid overactive bladder (OAB) and myasthenia gravis successfully treated with intra-detrusor Botox.

Downloads

Download data is not yet available.

Author Biographies

Ian Wright, vesia [Alberta Bladder Centre]

Urology Fellow

Richard Baverstock, vesia [Alberta Bladder Centre] University of Calgary

Urology (MD, FRCSC)

Downloads

Published

2016-05-12

How to Cite

Wright, I., Civitarese, A., & Baverstock, R. (2016). The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis. Canadian Urological Association Journal, 10(5-6), E184–5. https://doi.org/10.5489/cuaj.3678

Issue

Section

Residents' Room